<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bivalirudin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bivalirudin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bivalirudin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11926" href="/d/html/11926.html" rel="external">see "Bivalirudin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F141778"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Angiomax;</li>
<li>Bivalirudin RTU [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866092"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Angiomax</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F141795"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant;</li>
<li>
                        Anticoagulant, Direct Thrombin Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F141781"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2a33dbc9-44ea-49f3-8794-d173f3cb3f0e">Cardiac surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac surgery (alternative to heparin) (</b>
<b>off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients with heparin allergy (eg, allergy to pork containing products) or heparin-induced thrombocytopenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-30482768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Intraoperative:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Off-pump:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial bolus: </i>0.75 mg/kg followed by continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720385'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance continuous infusion</i>: 1.75 mg/kg/hour to maintain ACT &gt;300 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720385'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> If patient needs to go on-pump, some have recommended an additional 0.25 mg/kg bolus and increasing the infusion rate to 2.5 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Angiomax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Angiomax.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>On-pump:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial bolus</i>: 1 to 1.25 mg/kg followed by continuous infusion; add 50 mg bolus to priming solution of cardiopulmonary bypass (CPB) circuit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16515902','lexi-content-ref-17257990','lexi-content-ref-27230048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16515902','lexi-content-ref-17257990','lexi-content-ref-27230048'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance continuous infusion</i>: 2.5 mg/kg/hour to maintain ACT &gt;2.5 times baseline; if ACT is subtherapeutic may administer an additional bolus of 0.1 to 0.5 mg/kg and increase infusion by 0.25 mg/kg/hour. Discontinue infusion 10 to 15 minutes prior to weaning from CPB (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16515902','lexi-content-ref-17257990','lexi-content-ref-27230048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16515902','lexi-content-ref-17257990','lexi-content-ref-27230048'])">Ref</a></span>). <b>Note:</b> Special maneuvers are needed to prevent stasis and clotting within the CPB circuit during and after surgery. When weaning from CPB, may keep blood recirculating through the circuit and administer 50 mg <b>into the CPB circuit</b> followed by a continuous infusion of 50 mg/hour <b>into the CPB circuit; </b>continue infusion until it is evident the patient will not require an urgent return to CPB. If separation from circuit does not occur within 20 minutes of stopping infusion, redose patient with 0.5 mg/kg and restart infusion at 2.5 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17257990','lexi-content-ref-27230048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17257990','lexi-content-ref-27230048'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="268855ac-c424-450c-ab52-a51bfe383ea4">Heparin-induced thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia (HIT) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial dose: 0.15 to 0.2 mg/kg/hour; adjust to aPTT 1.5 to 2.5 times baseline value (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-30482768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Transitioning from bivalirudin to an oral anticoagulant:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Transitioning from bivalirudin to warfarin:</i> Start warfarin and continue bivalirudin until INR is within therapeutic range; overlap bivalirudin with warfarin until INR is ≥2 for at least 2 measurements taken ~24 hours apart and for a minimum of 5 days; recheck INR after effect of bivalirudin has dissipated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-22315270','lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-22315270','lexi-content-ref-Dager.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Transitioning from bivalirudin to a direct-acting oral anticoagulant:</i> Start direct-acting oral anticoagulant when bivalirudin infusion is stopped (consult local protocol if the aPTT is above the target range) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dager.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dager.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="734f50d5-ef6c-410b-b681-a75c1e1b56d5">Ischemic heart disease, percutaneous coronary intervention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ischemic heart disease, percutaneous coronary intervention (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Includes patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome or when PCI is chosen for stable ischemic heart disease. Consider for use as an alternative to heparin. Use in combination with an appropriate antithrombotic regimen. If unfractionated heparin is initiated then switched to bivalirudin prior to PCI, discontinue unfractionated heparin and wait 30 minutes before starting bivalirudin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-15304466','lexi-content-ref-17124018','lexi-content-ref-18499566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-15304466','lexi-content-ref-17124018','lexi-content-ref-18499566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If initiating bivalirudin <b>during</b> PCI</i>: Initial: 0.75 mg/kg bolus immediately prior to procedure, followed immediately by 1.75 mg/kg/hour for the duration of procedure. After the procedure, may continue the infusion at 1.75 mg/kg/hour for up to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If initiating bivalirudin <b>prior to</b> PCI or diagnostic angiography (off-label):</i> Initial: 0.1 mg/kg bolus, followed by 0.25 mg/kg/hour; continue until diagnostic angiography or PCI. If PCI is necessary, give an additional bolus of 0.5 mg/kg and increase infusion to 1.75 mg/kg/hour during PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-17124018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-17124018'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990610"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Percutaneous coronary intervention: </b>IV: <b>Note:</b> CrCl may be estimated using the Cockcroft-Gault equation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25712269','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25712269','lexi-content-ref-Manu.1'])">Ref</a></span>). Recommendations are only applicable if initiating bivalirudin during percutaneous coronary intervention.</p>
<p style="text-indent:-2em;margin-left:4em;">Bolus: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: 1.75 mg/kg/hour.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: 1 mg/kg/hour.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Dialyzable (25%): 0.25 mg/kg/hour.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV: <b>Note:</b> Initial continuous infusion doses based on estimated CrCl using Cockcroft Gault. Dosing is derived from the results of retrospective, observational data from single-center studies. For higher targets or urgent need to more rapidly achieve therapeutic levels, it may be appropriate to choose a starting dose at the higher end of the recommended ranges. Refer to institution-specific protocols for titration.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;60 mL/minute: No dosage adjustment necessary; however, based on observational data, a range of 0.13 to 0.16 mg/kg/hour may achieve a target aPTT of 1.5 to 2.5 times patient baseline or normal range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18752382','lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18752382','lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 60 mL/minute: Initial: 0.08 to 0.12 mg/kg/hour; titrate to achieve target aPTT of 1.5 to 2.5 times patient baseline or normal range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18752382','lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18752382','lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Initial: 0.04 to 0.07 mg/kg/hour; titrate to achieve target aPTT of 1.5 to 2.5 times patient baseline or normal range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18752382','lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18752382','lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Dialyzable (25% over 4 hours): Initial: 0.04 to 0.08 mg/kg/hour; titrate to achieve target aPTT of 1.5 to 2.5 times patient baseline or normal range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21923585','lexi-content-ref-21881032','lexi-content-ref-22271374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CRRT: <b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations assume high-flux dialyzers and flow rates of ~1,500 to 3,000 mL/hour, unless otherwise noted. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:8em;">CVVH/CVVHD/CVVHDF: IV: Initial: 0.03 to 0.07 mg/kg/hour; titrate to achieve target aPTT of 1.5 to 2.5 times patient baseline or normal range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chanas.1','lexi-content-ref-16553502','lexi-content-ref-21923585','lexi-content-ref-21881032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chanas.1','lexi-content-ref-16553502','lexi-content-ref-21923585','lexi-content-ref-21881032'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged intermittent renal replacement therapy (eg, sustained low-efficiency diafiltration): <b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:8em;">Prolonged intermittent renal replacement therapy (6- to 8-hour session, 6 days per week): IV: Initial: 0.09 mg/kg/hour; titrate to achieve target aPTT of 1.5 to 2.5 times patient baseline or normal range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21881032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21881032'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987674"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary (Seybert 2006). In patients treated for HIT (off-label use), patients with hepatic impairment required slightly lower doses compared to previous reports for patients with normal hepatic function; however, the lower doses may have been required due to critical illness instead of hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16553502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16553502'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F56872276"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, and 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Use <b>actual body weight</b> for weight-based dose calculations, then titrate to clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Careful monitoring for bleeding is warranted, especially in patients with BMI ≥50 kg/m<sup>2</sup>, severe renal impairment, or those that are dialysis dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations: </b>There are limited data evaluating the effect of obesity on dosing requirements for bivalirudin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29509886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29509886'])">Ref</a></span>). Clearance of bivalirudin is strongly dependent upon renal function. The half-life of bivalirudin increases from ~25 minutes to 57 minutes in patients with severe renal impairment (eGFR &lt;30 mL/minute), and up to 3.5 hours between dialysis sessions for patients that require renal replacement. A small retrospective study compared actual body weight, adjusted body weight, and ideal body weight in patients treated for heparin-induced thrombocytopenia, and actual body weight provided the closest correlation to rates observed at the target aPTT. Furthermore, this study did not identify a clear difference in clinical outcomes, including dose to achieve goal aPTT, between patients with obesity (BMI range: 30.1 to 56.2 kg/m<sup>2</sup>), and patients without obesity that received weight-based dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22392825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22392825'])">Ref</a></span>). In a registry of 16,783 patients undergoing percutaneous coronary intervention, an increase in risk of major bleeding was not observed with increasing BMI, including class 3 obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20569731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20569731'])">Ref</a></span>). Use of alternate weight descriptors, such as ideal body weight and adjusted body weight, are not recommended due to the risk for under dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F141782"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. No dosage adjustment is needed in elderly patients with normal renal function. Puncture site hemorrhage and catheterization site hemorrhage were seen in more patients ≥65 years of age than in patients &lt;65 years of age.</p></div>
<div class="block adr drugH1Div" id="F141750"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombosis (acute stent thrombosis [&lt;4 hours] in patients with STEMI undergoing primary PCI: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (including intracranial hemorrhage, major hemorrhage, and retroperitoneal hemorrhage: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Major hemorrhage, retroperitoneal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac tamponade, coronary thrombosis (during PCI, including intracoronary brachytherapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased INR, pulmonary hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F141763"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis) to bivalirudin or any component of the formulation; active major bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Major blood clotting disorders; acute gastric or duodenal ulcer; cerebral hemorrhage; severe cerebrospinal trauma; bacterial endocarditis; severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; proximal use of spinal/epidural anesthesia</p></div>
<div class="block war drugH1Div" id="F141748"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute stent thrombosis: In patients with STEMI undergoing PCI, acute stent thrombosis (some fatal) occurring within 4 hours of the procedure was observed at a greater frequency as compared to those treated with heparin. Patients should remain for at least 24 hours in a facility capable of managing ischemic complications; monitor for signs and symptoms consistent with myocardial ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: The most common complication is bleeding. Certain patients are at increased risk of bleeding; risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; recent puncture of large vessels or organ biopsy; recent CVA, stroke, intracerebral surgery, or other neuraxial procedure; severe uncontrolled hypertension; renal impairment; recent major surgery; recent major bleeding (intracranial, GI, intraocular, or pulmonary). Monitor for signs and symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombus formation: Increased risk of intracoronary thrombus formation (some fatal, as reported by the manufacturer) has been reported with use in gamma brachytherapy even with the use of higher doses as compared to doses used for beta radiation (Kuchulakanti 2005). If used during brachytherapy, maintain meticulous catheter technique with frequent aspiration and flushing while minimizing conditions of stasis within the catheter or vessels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage reduction required.</p></div>
<div class="block foc drugH1Div" id="F141758"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bivalirudin RTU: 250 mg/50 mL (50 mL [DSC]) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/50 mL (50 mL); 500 mg/100 mL in NaCl 0.9% (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Angiomax: 250 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Angiomax: 250 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F141744"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323020"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bivalirudin Trifluoroacetate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/50 mL (per mL): $1.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Angiomax Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $1,170.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Bivalirudin Trifluoroacetate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $90.00 - $1,137.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866093"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Angiomax: 250 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F141760"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV administration only. After initial bolus dose (when recommended), administer as a continuous infusion; refer to indication-specific infusion rates in dosing for detailed recommendations.</p></div>
<div class="block uica drugH1Div" id="F14471292"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 250 mg in 50 mL (concentration: 5 mg/mL) of D5W or NS</p></div>
<div class="block use drugH1Div" id="F141759"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Percutaneous coronary intervention:</b> Anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia/thrombosis syndrome (HIT/TS)</p></div>
<div class="block off-label drugH1Div" id="F25475242"><span class="drugH1">Use: Off-Label: Adult</span><p>Cardiac surgery (alternative to heparin); Heparin-induced thrombocytopenia, complicated by thrombosis</p></div>
<div class="block mst drugH1Div" id="F5174519"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">National Patient Safety Goals:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have approved protocols and evidence-based practice guidelines in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes medication selection, dosing (including adjustments for age, renal function, or liver function), drug-drug interactions, drug-food interactions, other applicable risk factors, monitoring, patient and family education, proper administration, reversal of anticoagulation, management of bleeding events, and perioperative management. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism during procedures or hospitalizations (NPSG.03.05.01).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298872"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F141752"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F141766"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Bivalirudin is used in conjunction with aspirin, which may lead to maternal or fetal adverse effects, especially during the third trimester. Use of parenteral direct thrombin inhibitors in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt 2012).</p></div>
<div class="block brc drugH1Div" id="F16248962"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bivalirudin is present in breast milk. The manufacturer recommends that caution be exercised when administering bivalirudin to breastfeeding women.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F141756"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ACT; aPTT; PT/INR; signs/symptoms of bleeding.</p></div>
<div class="block pha drugH1Div" id="F141747"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bivalirudin acts as a specific and reversible direct thrombin inhibitor; it binds to the catalytic and anionic exosite of both circulating and clot-bound thrombin. Catalytic binding site occupation functionally inhibits coagulant effects by preventing thrombin-mediated cleavage of fibrinogen to fibrin monomers, and activation of factors V, VIII, and XIII. Shows linear dose- and concentration-dependent prolongation of ACT, aPTT, PT, and TT.</p></div>
<div class="block phk drugH1Div" id="F141762"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Immediate</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Coagulation times return to baseline ~1 hour following discontinuation of infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: Does not bind other than thrombin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Proteolytic cleavage</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Normal renal function and mild renal impairment: 25 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate renal impairment: 34 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Severe renal impairment: 57 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis: 3.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (20%), glomerular filtration, tubular secretion, and tubular reabsorption</p></div>
<div class="block phksp drugH1Div" id="F51154029"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced by 21% in moderate and severe renal impairment and by 70% in dialysis patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F141767"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Amuprux</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin accord</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Angiomax | Apo bivalirudin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bivalirudin accord</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Tai jia ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Angiomax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin accord | Bivalirudin cipla</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bivacard</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudina accord | Bivalirudina sala</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin accord | Bivalirudin Reig Jofre</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudine Accord</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin Reig Jofre</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Angiox</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Angiox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Angiox</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bivacard | Bivacs | Bivaflo | Bivamax | Bivasave | Bivastat | Flopace | Nubimax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bivalirudina accord</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Angiox</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Angiox</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudine Accord</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Angiox</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Angiomax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Angiomax</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biwalirudyna accord</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Angiomax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin accord</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Angiox</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin j</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin accord | Bivalirudin Reig Jofre</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Angiox | Bivalirudin accord</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bivacard</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Advanced Cardiac Therapies Improving Outcomes Network (ACTION). Direct thrombin inhibitor (DTI) harmonization protocol for VADs. https://static1.squarespace.com/static/59cc02baf43b554ffccb10d8/t/6022a69993081f556a043098/1612883609727/ACTION+DTI+Harmonization+Protocol+4_24_20.pdf. Updated April 24, 2020. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315269">
<a name="22315269"></a>Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(suppl 2):e44S-e88S. doi:10.1378/chest.11-2292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22315269/pubmed" id="22315269" target="_blank">22315269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12777673">
<a name="12777673"></a>Allie DE, Lirtzman MD, Wyatt CH, et al, “Bivalirudin as a Foundation Anticoagulant in Peripheral Vascular Disease: A Safe and Feasible Alternative for Renal and Iliac Interventions," <i>J Invasive Cardiol</i>, 2003, 15(6):334-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12777673/pubmed" id="12777673" target="_blank">12777673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Angiomax (bivalirudin) [prescribing information]. Princeton, NJ: Sandoz Inc; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Angiomax.1">
<a name="Angiomax.1"></a>Angiomax (bivalirudin) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc.; September 2016.</div>
</li>
<li>
<div class="reference">
                  Angiomax RTU (bivalirudin) [prescribing information]. Princeton, NJ: Sandoz Inc; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588276">
<a name="12588276"></a>Antman EM, “Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?” <i>JAMA</i>, 2003, 289:903-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12588276/pubmed" id="12588276" target="_blank">12588276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12355033">
<a name="12355033"></a>Aggarwal A, Sobel BE, and Schneider DJ, “Decreased Platelet Reactivity in Blood Anticoagulated With Bivalirudin or Enoxaparin Compared With Unfractionated Heparin: Implications for Coronary Intervention,” <i>J Thromb Thrombolysis</i>, 2002, 13:161-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12355033/pubmed" id="12355033" target="_blank">12355033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11717596">
<a name="11717596"></a>Bittl JA, Chaitman BR, Feit F, et al, “Bivalirudin Versus Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina: Final Report Reanalysis of the Bivalirudin Angioplasty Study,” <i>Am Heart J</i>, 2001, 142:952-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/11717596/pubmed" id="11717596" target="_blank">11717596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7643883">
<a name="7643883"></a>Bittl JA, Strony J, Brinker JA, et al, “Treatment With Bivalirudin (Hirulog) as Compared With Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina. Hirulog Angioplasty Study Investigators,” <i>N Engl J Med</i>, 1995, 333(12):764-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/7643883/pubmed" id="7643883" target="_blank">7643883</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bivalirudin injection [prescribing information]. Deerfield, IL: Baxter Healthcare; January 2021.</div>
</li>
<li>
<div class="reference">
                  Bivalirudin injection [prescribing information]. Deerfield, IL: Baxter Healthcare; May 2018.</div>
</li>
<li>
<div class="reference">
                  Bivalirudin injection [prescribing information]. Princeton, NJ: Dr. Reddy's Laboratories, Inc; July 2019.</div>
</li>
<li>
<div class="reference">
                  Bivalirudin injection RTU [prescribing information]. Princeton, NJ: MAIA Pharmaceuticals Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chanas.1">
<a name="Chanas.1"></a>Chanas T, Palkimas S, Maitland HS, Liszewski A. Evaluation of the use of argatroban or bivalirudin for the management of suspected heparin-induced thrombocytopenia in the setting of continuous renal replacement therapy. <i>Clin Med Insights: Trauma Intensive Med</i>. 2019. doi: 10.1177/1179560319846452.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482768">
<a name="30482768"></a>Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Adv.</i> 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/30482768/pubmed" id="30482768" target="_blank">30482768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dager.1">
<a name="Dager.1"></a>Dager WE. <i>Anticoagulation Therapy</i>. 2nd ed. American Society of Health-System Pharmacists; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17381384">
<a name="17381384"></a>Dager WE, Dougherty JA, Nguyen PH, et al, “Heparin-Induced Thrombocytopenia: Treatment Options and Special Considerations,” <i>Pharmacotherapy</i>, 2007, 27(4):564-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17381384/pubmed" id="17381384" target="_blank">17381384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553503">
<a name="16553503"></a>Dang CH, Durkalski VL, and Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. <i>Pharmacotherapy</i>. 2006;26(4):461-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16553503/pubmed" id="16553503" target="_blank">16553503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21636031">
<a name="21636031"></a>Dangas GD, Mehran R, Nikolsky E, et al, “Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction: The HORIZONS-SWITCH Analysis,” <i>J Am Coll Cardiol</i>, 2001, 57(23):2309-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/21636031/pubmed" id="21636031" target="_blank">21636031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12537226">
<a name="12537226"></a>Davis Z, Anderson R, Short D, et al, “Favorable Outcome With Bivalirudin Anticoagulation During Cardiopulmonary Bypass,” <i>Ann Thorac Surg</i>, 2003, 75(1):264-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12537226/pubmed" id="12537226" target="_blank">12537226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20569731">
<a name="20569731"></a>Delhaye C, Wakabayashi K, Maluenda G, et al. Body mass index and bleeding complications after percutaneous coronary intervention: does bivalirudin make a difference? <i>Am Heart J</i>. 2010;159(6):1139-1146. doi:10.1016/j.ahj.2010.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/20569731/pubmed" id="20569731" target="_blank">20569731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17720385">
<a name="17720385"></a>Dyke CM, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. <i>Ann Thorac Surg</i>. 2007;84(3):836-840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17720385/pubmed" id="17720385" target="_blank">17720385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16515902">
<a name="16515902"></a>Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. <i>J Thorac Cardiovasc Surg</i>. 2006;131(3):533-539. doi:10.1016/j.jtcvs.2005.09.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16515902/pubmed" id="16515902" target="_blank">16515902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28844201">
<a name="28844201"></a>Erlinge D, Omerovic E, Frobert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. <i>N Engl J Med.</i> 2017;377:1132-1142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/28844201/pubmed" id="28844201" target="_blank">28844201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.;</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21433272">
<a name="21433272"></a>Forbes TJ, Hijazi ZM, Young G, et al. Pediatric catheterization laboratory anticoagulation with bivalirudin. <i>Catheter Cardiovasc Interv</i>. 2011;77(5):671-679. doi:10.1002/ccd.22817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/21433272/pubmed" id="21433272" target="_blank">21433272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7641350">
<a name="7641350"></a>Fuchs J and Cannon CP, “Hirulog in the Treatment of Unstable Angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial,” <i>Circulation</i>, 1995, 92(4):727-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/7641350/pubmed" id="7641350" target="_blank">7641350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32404633">
<a name="32404633"></a>Hamzah M, Jarden AM, Ezetendu C, Stewart R. Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation. <i>Pediatr Crit Care Med</i>. 2020;21(9):827-834. doi:10.1097/PCC.0000000000002384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/32404633/pubmed" id="32404633" target="_blank">32404633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25775052">
<a name="25775052"></a>Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: The BRIGHT randomized clinical trial. <i>JAMA.</i> 2015;313(13):1336-1346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/25775052/pubmed" id="25775052" target="_blank">25775052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482701">
<a name="30482701"></a>Hasija S, Talwar S, Makhija N, et al. Randomized controlled trial of heparin versus bivalirudin anticoagulation in acyanotic children undergoing open heart surgery. <i>J Cardiothorac Vasc Anesth</i>. 2018;32(6):2633-2640. doi:10.1053/j.jvca.2018.04.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/30482701/pubmed" id="30482701" target="_blank">30482701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553502">
<a name="16553502"></a>Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. <i>Pharmacotherapy.</i> 2006;26(4):452-460. doi: 10.1592/phco.26.4.452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16553502/pubmed" id="16553502" target="_blank">16553502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18752382">
<a name="18752382"></a>Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. <i>Pharmacotherapy.</i> 2008;28(9):1115-1124. doi: 10.1592/phco.28.9.1115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/18752382/pubmed" id="18752382" target="_blank">18752382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12707125">
<a name="12707125"></a>Koster A, Chew D, Grundel M, et al. An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An <i>In Vitro</i> Study. <i>Anesth Analg.</i> 2003;96(5):1316-1319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12707125/pubmed" id="12707125" target="_blank">12707125</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Koster A, Chew D, Grundel M, et al. Bivalirudin Monitored With the Ecarin Clotting Time for Anticoagulation During Cardiopulmonary Bypass. <i>Anesth Analg.</i> 2003;96(2):383-386.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17257990">
<a name="17257990"></a>Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. <i>Ann Thorac Surg.</i> 2007;83(2):572-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17257990/pubmed" id="17257990" target="_blank">17257990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14759391">
<a name="14759391"></a>Koster A, Spiess B, Chew DP, et al. Effectiveness of Bivalirudin as a Replacement for Heparin During Cardiopulmonary Bypass in Patients Undergoing Coronary Artery Bypass Grafting. <i>Am J Cardiol.</i> 2004;93(3):356-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/14759391/pubmed" id="14759391" target="_blank">14759391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16209990">
<a name="16209990"></a>Kuchulakanti P, Wolfram R, Torguson R, et al. Brachytherapy and bivalirudin evaluation study. <i>Am Heart J.</i> 2005;150(4):832-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16209990/pubmed" id="16209990" target="_blank">16209990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588269">
<a name="12588269"></a>Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. REPLACE-2 Randomized Trial. <i>JAMA.</i> 2003;289(7):853-863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12588269/pubmed" id="12588269" target="_blank">12588269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15304466">
<a name="15304466"></a>Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-Term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization: REPLACE-2 Randomized Trial. <i>JAMA.</i> 2004;292(6):696-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/15304466/pubmed" id="15304466" target="_blank">15304466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12040347">
<a name="12040347"></a>Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin With Planned or Provisional Abciximab Versus Low-Dose Heparin and Abciximab During Percutaneous Coronary Revascularization: Results of the Comparison of Abciximab Complications With Hirulog for Ischemic Events Trial (CACHET). <i>Am Heart J. </i>2002;143(5):847-853.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12040347/pubmed" id="12040347" target="_blank">12040347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins L, Dans AL, Moores LK, et al. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):e495S-e530S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14992900">
<a name="14992900"></a>Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin Versus Heparin and Protamine in Off-Pump Coronary Artery Bypass Surgery. <i>Ann Thorac Surg.</i> 2004;77:925-931.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/14992900/pubmed" id="14992900" target="_blank">14992900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23648880">
<a name="23648880"></a>Nagle EL, Dager WE, Duby JJ, et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. <i>Pediatr Crit Care Med</i>. 2013;14(4):e182-e188. doi:10.1097/PCC.0b013e31827200b6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/23648880/pubmed" id="23648880" target="_blank">23648880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10520777">
<a name="10520777"></a>Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant Hirudin (Lepirudin) for the Improvement of Thrombolysis With Streptokinase in Patients With Acute Myocardial Infarction: Results of the HIT-4 Trial. <i>J Am Coll Cardiol.</i> 1999;34(4):966-973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/10520777/pubmed" id="10520777" target="_blank">10520777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099212">
<a name="22099212"></a>Ranucci M, Ballotta A, Kandil H, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. <i>Crit Care</i>. 2011;15(6):R275. doi:10.1186/cc10556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22099212/pubmed" id="22099212" target="_blank">22099212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18819124">
<a name="18819124"></a>Rayapudi S, Torres A Jr, Deshpande GG, et al. Bivalirudin for anticoagulation in children. <i>Pediatr Blood Cancer</i>. 2008;51(6):798-801. doi:10.1002/pbc.21731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/18819124/pubmed" id="18819124" target="_blank">18819124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11156732">
<a name="11156732"></a>Robson R. The Use of Bivalirudin in Patients With Renal Impairment. <i>J Invasive Cardiol.</i> 2000;12:33F-36F.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/11156732/pubmed" id="11156732" target="_blank">11156732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29509886">
<a name="29509886"></a>Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>Eur Heart J</i>. 2018;39(19):1672-1686f. doi:10.1093/eurheartj/ehy066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/29509886/pubmed" id="29509886" target="_blank">29509886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21923585">
<a name="21923585"></a>Runyan CL, Cabral KP, Riker RR, et al. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia. <i>Pharmacotherapy</i>. 2011;31(9):850-856. doi: 10.1592/phco.31.9.850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/21923585/pubmed" id="21923585" target="_blank">21923585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27230048">
<a name="27230048"></a>Salter BS, Weiner MM, Trinh MA, et al. Heparin-induced thrombocytopenia: a comprehensive clinical review. <i>J Am Coll Cardiol</i>. 2016;67(21):2519-2532. doi:10.1016/j.jacc.2016.02.073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/27230048/pubmed" id="27230048" target="_blank">27230048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33870916">
<a name="33870916"></a>Seelhammer TG, Bohman JK, Schulte PJ, Hanson AC, Aganga DO. Comparison of bivalirudin versus heparin for maintenance systemic anticoagulation during adult and pediatric extracorporeal membrane oxygenation. <i>Crit Care Med</i>. 2021;49(9):1481-1492. doi:10.1097/CCM.0000000000005033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/33870916/pubmed" id="33870916" target="_blank">33870916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16466327">
<a name="16466327"></a>Seybert AL, Coons JC, Zerumsky K. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? <i>Pharmacotherapy. </i>2006;26(2):229-241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16466327/pubmed" id="16466327" target="_blank">16466327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12840239">
<a name="12840239"></a>Shammas NW, Lemke JH, Dippel EJ, et al. Bivalirudin in Peripheral Vascular Interventions: A Single Center Experience. <i>J Invasive Cardiol.</i> 2003;15(7):401-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12840239/pubmed" id="12840239" target="_blank">12840239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25002178">
<a name="25002178"></a>Shahzad A, Kemp I, Mars C, et al; for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial [published online July 5, 2014]. <i>Lancet</i>. doi: 10.1016/S0140-6736(14)60924-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/25002178/pubmed" id="25002178" target="_blank">25002178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16515924">
<a name="16515924"></a>Smedira NG, Dyke CM, Koster A, et al. Anticoagulation With Bivalirudin For Off-Pump Coronary Artery Bypass Grafting: The Results Of The EVOLUTION-OFF Study. <i>J Thorac Cardiovasc Surg.</i> 2006;131(3):686-692.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16515924/pubmed" id="16515924" target="_blank">16515924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24171490">
<a name="24171490"></a>Steg PG, van 't Hof A, Hamm CW, et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. <i>N Engl J Med</i>. 2013;369(23):2207-2217. doi: 10.1056/NEJMoa1311096.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/24171490/pubmed" id="24171490" target="_blank">24171490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17124018">
<a name="17124018"></a>Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for Patients With Acute Coronary Syndromes. <i>N Engl J Med.</i> 2006;355(21):2203-2216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17124018/pubmed" id="17124018" target="_blank">17124018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18499566">
<a name="18499566"></a>Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin During Primary PCI in Acute Myocardial Infarction. <i>N Engl J Med. </i>2008;358(21):2218-2230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/18499566/pubmed" id="18499566" target="_blank">18499566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21881032">
<a name="21881032"></a>Tsu LV, Dager WE. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. <i>Ann Pharmacother.</i> 2011;45(10):1185-1192. doi: 10.1345/aph.1Q177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/21881032/pubmed" id="21881032" target="_blank">21881032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22392825">
<a name="22392825"></a>Tsu LV, Dager WE. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia. <i>Pharmacotherapy</i>. 2012;32(1):20-26. doi:10.1002/PHAR.1016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22392825/pubmed" id="22392825" target="_blank">22392825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324049">
<a name="26324049"></a>Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. <i>N Engl J Med</i>. 2015;373(11):997-1009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/26324049/pubmed" id="26324049" target="_blank">26324049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12643418">
<a name="12643418"></a>Vasquez JC, Vichiendilokkul A, Mahmood S, et al. Anticoagulation With Bivalirudin During Cardiopulmonary Bypass in Cardiac Surgery. <i>Ann Thorac Surg.</i> 2002;74(6):2177-2179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12643418/pubmed" id="12643418" target="_blank">12643418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25712269">
<a name="25712269"></a>Washam JB, Herzog CA, Beitelshees AL, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Functional Genomics and Translational Biology, Council on the Kidney in Cardiovascular Disease, Council on Quality of Care and Outcomes Research. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(12):1123-1149. doi: 10.1161/CIR.0000000000000183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/25712269/pubmed" id="25712269" target="_blank">25712269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22271374">
<a name="22271374"></a>Wisler JW, Washam JB, Becker RC. Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. <i>J Thromb Thrombolysis</i>. 2012;33(3):287-295. doi: 10.1007/s11239-011-0677-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22271374/pubmed" id="22271374" target="_blank">22271374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17663736">
<a name="17663736"></a>Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants &lt;6 months of age with thrombosis. <i>J Thromb Haemost</i>. 2007;5(8):1654-1659. doi:10.1111/j.1538-7836.2007.02623.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17663736/pubmed" id="17663736" target="_blank">17663736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16819775">
<a name="16819775"></a>Zamora R. Successful anticoagulation with bivalirudin in antithrombin-deficient pediatric patient undergoing stent placement. <i>Catheter Cardiovasc Interv</i>. 2006;68(2):292-295. doi: 10.1002/ccd.20739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16819775/pubmed" id="16819775" target="_blank">16819775</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8792 Version 362.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
